A protein plucked from common soil bacteria and paired with a fatty acid can destroy colorectal cancer cells in laboratory dishes, Swedish researchers reported in a study published in Cell Death Discovery earlier this year. The engineered complex, called NheA-O, punches holes in cancer cell membranes and cripples their energy-producing mitochondria, triggering a form of cell death the team describes as “potently tumoricidal.”
The work, led by scientists at Umeå University, offers a fresh angle on drug design: repurposing a bacterial toxin component that evolved to attack cell surfaces and redirecting it against tumors. But the results so far are confined to cell lines in a lab, not living organisms or patients, and significant hurdles remain before the concept could reach a clinic.
Why colorectal cancer needs new weapons
Colorectal cancer is the third most commonly diagnosed cancer worldwide and the second leading cause of cancer death, according to the World Health Organization. Standard treatments include surgery, chemotherapy and targeted therapies, yet advanced cases frequently resist available drugs. Researchers have been hunting for agents that attack cancer cells through mechanisms distinct from conventional chemotherapy, and bacterial proteins represent one largely untapped source.
How NheA-O was built and what it does
NheA is one of three subunits of the nonhemolytic enterotoxin (Nhe) produced by Bacillus cereus and the closely related Bacillus thuringiensis, bacteria widespread in soil. Structural studies classify NheA within the ClyA superfamily of pore-forming toxins, proteins that naturally insert into and disrupt cell membranes.
To create NheA-O, the Umeå team mixed purified NheA with sodium oleate, a salt of the common fatty acid oleic acid. The resulting complex behaves differently from the native toxin. In the Nhe system, the three subunits assemble sequentially on a target cell’s surface and are not interchangeable, as documented in earlier work on Nhe assembly. By isolating NheA and combining it with oleate instead of its natural partners, the researchers created a molecule with a distinct mode of action tuned toward cancer cells.
According to the Cell Death Discovery paper, NheA-O binds to the outer membranes of colorectal cancer cells, disrupts their structure and triggers what the authors call ferroptosis-like cell death. Ferroptosis is a regulated form of cell death driven by the accumulation of toxic lipid peroxides. The study’s mechanistic data show that NheA-O inhibits the beta-catenin-GPX4 signaling axis, a pathway cancer cells rely on to neutralize those peroxides and survive. With that defense knocked out and their membranes compromised, the cancer cells also suffered mitochondrial dysfunction, losing the organelles responsible for energy production.
“The complex targets cancer cell mitochondria,” the Umeå University team noted in an institutional summary of the findings, framing the approach as a way to engineer naturally occurring soil-bacteria proteins into tumor-killing agents.
A concept with precedent
NheA-O is not the first protein-oleate complex shown to kill tumor cells. A well-studied molecule called HAMLET, formed from a human milk protein and oleic acid, remodels tumor cell membranes in a receptor-independent manner and triggers cancer cell death while leaving healthy primary cells less affected, according to research published in Scientific Reports.
HAMLET provided a conceptual template: pair a membrane-active protein with oleate and the resulting complex can selectively damage cancer cells. NheA-O extends that template to a bacterial toxin component, but the two complexes use different proteins and have been tested in different tumor models. Whether NheA-O shares HAMLET’s relative sparing of normal cells has not been directly demonstrated.
What the study does not show
Several important questions remain unanswered. The Cell Death Discovery paper reports results exclusively from colorectal cancer cell lines grown in laboratory dishes. No animal studies or human trials are described, so how NheA-O behaves in a living body, including how it interacts with blood, organs and the immune system, is unknown.
Selectivity is a particular concern. While the HAMLET literature suggests protein-oleate complexes can discriminate between tumor and healthy cells, the NheA-O study does not include direct comparisons with non-cancerous cells. Assuming the two complexes will behave identically on that front would be premature.
Durability and resistance also remain open. The published experiments document potent killing under controlled conditions, but they do not describe repeated dosing, chronic exposure or whether surviving cells might adapt. Questions about long-term efficacy and possible resistance mechanisms will require further investigation.
The study tested NheA-O against colorectal cancer cell lines without specifying a range of genetic backgrounds or molecular subtypes. Colorectal tumors vary widely in their beta-catenin and GPX4 biology, and whether NheA-O would work equally well across that spectrum, or against other cancer types, is not addressed.
Finally, there is no published information on manufacturing NheA-O at scale, formulating it as a drug product or navigating regulatory requirements. Moving from a laboratory proof of concept to a therapeutic candidate typically takes years of preclinical development, including animal toxicology studies, before human trials can begin.
Where the research stands now
The strongest takeaway from the current evidence is specific and bounded: in controlled lab experiments published in a peer-reviewed journal, an engineered complex built from a Bacillus toxin subunit and sodium oleate killed colorectal cancer cells by attacking their membranes and energy machinery. Foundational work on the Nhe toxin system explains why NheA is naturally suited to membrane disruption, and the HAMLET literature shows the broader protein-oleate strategy has precedent.
What happens beyond the dish will determine whether NheA-O becomes more than an intriguing laboratory finding. Animal studies to assess safety, selectivity and pharmacokinetics are the logical next step. For now, the research adds a new entry to a growing catalog of bacterial proteins being re-engineered as potential cancer-fighting tools, a field that continues to expand as scientists look beyond conventional drug sources for ways to outmaneuver resistant tumors.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
